Protagonist Therapeutics Inc
|Market Cap (Intraday)||1.15B|
|2yr Forward PE||N/A|
Protagonist Therapeutics, Inc. Stock, NASDAQ:PTGX
Protagonist Therapeutics, Inc. engages in the research and development of novel constrained peptide-based drug candidates that address significant unmet medical needs. Its product pipeline include PTG-300, PTG-200, and PN-943 The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.